Program
coramitug
A development code. Also written as “NNC6019-0001”.
Its studies are led by Novo Nordisk.
Furthest: phase 3, since Sep 23, 20253 company-led studies, 2 open or runningNext primary completion: Feb 29, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 32 open or running | phase 3since Sep 23, 2025 | Jun 28, 2022 | Feb 29, 2028phase 2 · NCT06260709 |
- Named in Novo Nordisk’s own pipeline as
Coramitug in ATTR-CM
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 28, 2022First study: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)First studyNCT05442047 · 105 enrolled · United States, Canada, Czechia and more
- Feb 7, 2024Phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT06260709 · 88 enrolled · United States, Canada, Czechia and more
- Sep 23, 2025Phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT07207811 · 1,280 planned · United States, Argentina, Australia and more
Ahead
- Feb 29, 2028Primary completion: phase 2 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT06260709
- Jun 29, 2029Primary completion: phase 3 study in Transthyretin Amyloid Cardiomyopathy (ATTR CM)NCT07207811
TargetBeta
“Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart.”study summary, read by Claude · the study
Other programs on TTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tafamidisrule | Pfizer | phase 4 | 29 |
| acoramidisrule | BridgeBio | phase 4 | 15 |
| coramitug | Novo Nordisk | phase 1 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Argentina, Australia and more | 3 | Recruiting | Jun 29, 2029 | 1,280 |
| NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Canada, Czechia and more | 2 | Active, not recruiting | Feb 29, 2028 | 88 |
| NCT05442047Transthyretin Amyloid Cardiomyopathy (ATTR CM) · United States, Canada, Czechia and more | 2 | Completed | Feb 17, 2025 | 105 |
How it is read
Names in the registry
- “NNC6019-0001”, 3 entries
Codes read as this program: NNC60190001.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.